Transgene cervical cancer shot misses the mark in phase 2

Transgene's therapeutic vaccine for cervical and anogenital cancers has failed a phase 2 trial, but an efficacy signal warrants further study

Cancer vaccines come to the fore at AACR

This year’s American Association of Cancer Research (AACR) annual meeting saw a clutch of new studies on therapeutic vaccines that suggest the approach is starting to gain

Transgene starts trials of ‘digital’ cancer vaccine with NEC

Sillajen explains Pexa-Vec trial failure – it was the rescue...